How to Get Jatenzo in Arkansas: Telehealth, Labs, Prescriptions, and Pharmacies

What Jatenzo Is and Why Arkansas Patients Seek It

Jatenzo is the first oral testosterone replacement approved by the FDA that avoids first-pass hepatic metabolism. It is a lipophilic oral capsule absorbed via intestinal lymphatics, which means it does not carry the liver toxicity risk associated with 17-alpha-alkylated oral androgens from earlier decades. The FDA approved Jatenzo on March 27, 2019, for adult males with primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired) [1].

Swerdloff et al. (J Clin Endocrinol Metab, 2020, N=166) demonstrated that 87% of men titrated to the correct Jatenzo dose achieved average testosterone concentrations within the normal range (300, 1 to 000 ng/dL) over a 12-month open-label phase [2]. That trial established the pharmacokinetic basis for the twice-daily-with-food dosing requirement.

Arkansas men choose Jatenzo over topical gels or injections for several practical reasons. No skin-transfer risk exists for partners or children. No injection technique is required. The capsule fits into a standard twice-daily medication routine. For men in rural parts of the state, where specialty clinic appointments may require 60-plus miles of travel, a telehealth pathway to an oral medication is especially practical.

Testosterone deficiency affects roughly 2.1% of men aged 45, 54 and 12.3% of men aged 75 and older based on the 2011 Endocrine Society data referenced in their clinical practice guideline [3]. Arkansas has a substantial rural population; telehealth access removes geography as a barrier to care.

Who Can Legally Prescribe Jatenzo in Arkansas

Any Arkansas-licensed prescriber with Schedule III DEA registration can write a Jatenzo prescription. That includes physicians (MD, DO), nurse practitioners (NP) with Schedule III DEA authority, and physician assistants (PA) with DEA registration and a valid collaborative practice agreement where required. Arkansas law does not restrict testosterone prescribing to endocrinologists or urologists specifically [4].

Telehealth providers operating under Arkansas Code Annotated § 23-79-1602 may prescribe Jatenzo after conducting a synchronous audio-video evaluation that includes a review of qualifying laboratory results [4]. The Arkansas State Medical Board confirmed in 2020 guidance that a valid patient-physician relationship can be established via telehealth for Schedule III controlled substances when the prescriber holds an Arkansas license and the patient is physically located in Arkansas at the time of the visit.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We recommend measuring morning total testosterone as the initial diagnostic test" and specifies that the diagnosis requires "unequivocally low serum testosterone concentration" confirmed on at least two separate occasions [3]. Any prescriber in Arkansas is expected to follow that standard before initiating Jatenzo.

A practical prescriber hierarchy for Arkansas patients seeking Jatenzo:

1. Telehealth TRT/hormone clinic (fastest access, 1 to 3 day consult scheduling)
2. Primary care physician with DEA Schedule III registration (moderate wait, familiar with patient history)
3. Urologist or endocrinologist (longest wait, 4 to 12 weeks for new-patient appointments in many Arkansas markets, but preferred for complex cases involving secondary hypogonadism workup)

Required Labs Before a Jatenzo Prescription in Arkansas

Labs come first. No compliant Arkansas prescriber will issue Jatenzo without confirming biochemical hypogonadism. The minimum panel expected by Endocrine Society guidelines [3] and reflected in the Jatenzo FDA prescribing information [1] includes:

Testosterone axis

• Total testosterone: two separate morning draws (before 10 AM), fasting preferred, at least 24 hours apart
• LH (luteinizing hormone) and FSH to distinguish primary from secondary hypogonadism
• Free testosterone (calculated or equilibrium dialysis) when total testosterone is borderline (280 to 400 ng/dL) or SHBG is suspected to be abnormal

Safety baseline

• Hematocrit and CBC (Jatenzo raises hematocrit; the FDA label warns to monitor and consider dose reduction if hematocrit exceeds 54%) [1]
• PSA (prostate-specific antigen) to rule out occult prostate cancer before starting androgen therapy [3]
• Comprehensive metabolic panel including liver enzymes
• Blood pressure documented on the day of prescribing (Jatenzo is associated with blood pressure increases averaging 3 to 5 mmHg systolic in clinical trials; it is contraindicated in men with uncontrolled hypertension) [1]

Several Arkansas-based telehealth platforms that prescribe TRT partner with national laboratory networks including LabCorp and Quest Diagnostics, both of which have draw sites in Little Rock, Fort Smith, Fayetteville, Jonesboro, and smaller markets. Most patients can complete the required panel for $80, $220 out of pocket if ordering through a telehealth requisition, or at zero cost if drawing under commercial insurance that covers diagnostic labs [5].

The FDA label for Jatenzo specifies checking serum testosterone 3 to 5 hours after the morning dose at weeks 3, 4 of therapy to guide the first dose titration [1]. Arkansas prescribers using telehealth platforms are expected to build that follow-up lab into the initial treatment plan.

How the Telehealth Prescribing Process Works in Arkansas

Telehealth prescribing for Jatenzo in Arkansas follows a five-step sequence that most compliant platforms complete within 5, 10 business days.

Step 1: Intake and lab order (Day 1, 2). The patient completes an online intake questionnaire covering symptoms, past medical history, current medications, and contraindications. The platform issues a lab requisition electronically.

Step 2: Lab draw (Day 2, 5). The patient visits a local draw site. Testosterone must be drawn in the morning. Results are typically available in 24 to 72 hours from commercial labs.

Step 3: Synchronous video consult (Day 3, 7). A licensed Arkansas prescriber reviews the labs and conducts a real-time video visit. Vital signs including blood pressure are confirmed. The prescriber documents the diagnosis code (ICD-10 E29.1 for primary testicular failure or E23.0 for hypothalamic/pituitary hypogonadism) and confirms no contraindications exist.

Step 4: Prescription transmission (Day 3, 7, same day as consult). Because Jatenzo is a Schedule III controlled substance, prescriptions must comply with DEA 21 CFR Part 1306 rules. Electronic prescribing of controlled substances (EPCS) is permitted in Arkansas and is the standard method for telehealth platforms [6]. The prescriber transmits the script electronically to the patient's chosen pharmacy.

Step 5: Dispensing and delivery (Day 5, 14). Retail pharmacy dispensing typically takes 1, 3 business days. Mail-order pharmacies may take 3, 7 business days including shipping. Many patients in rural Arkansas opt for mail-order to avoid driving to a specialty pharmacy.

The DEA's 2023 proposed rule on telemedicine prescribing of controlled substances (Docket DEA-407) created uncertainty briefly, but the final interim rule effective May 2024 preserved the ability to prescribe Schedule III substances via telemedicine when a DEA-registered practitioner conducts a real-time audio-video evaluation [6]. Arkansas patients are covered under that federal framework.

Pharmacy Options for Jatenzo in Arkansas

Jatenzo is a brand-name product manufactured by Tolmar Pharmaceuticals. No generic oral testosterone undecanoate is currently FDA-approved in the United States. That limits dispensing to pharmacies stocking the brand.

Retail chain pharmacies. CVS, Walgreens, and Walmart pharmacies in larger Arkansas markets including Little Rock, Fayetteville, and Jonesboro can order Jatenzo through their standard wholesale channels. Stock is not always on the shelf; a 24, 48-hour special order is common. The GoodRx price for a 30-day supply (60 capsules at 237 mg) runs approximately $530, $620 as of early 2025. Manufacturer copay assistance through Tolmar's savings program may reduce the cost to $0, $99/month for commercially insured patients who qualify [7].

Specialty mail-order pharmacies. Pharmacies such as Help, Hallandale, and similar 503A compounding pharmacies licensed to operate in Arkansas cannot compound testosterone undecanoate in the branded Jatenzo formulation as a direct copy. However, 503A pharmacies hold state licensure to compound testosterone undecanoate capsules when a prescriber documents a specific patient need that the commercial product does not meet. This is a narrow legal pathway, not a general cost-saving route, and the formulation would differ from the FDA-approved Jatenzo product [8]. Patients and prescribers should discuss this distinction explicitly.

Prior authorization for Arkansas Medicaid. Arkansas Medicaid covers Jatenzo under the preferred drug list with prior authorization. The prescriber must document: (1) confirmed hypogonadism with two low morning testosterone values, (2) LH and FSH to classify the type, (3) failure or contraindication to at least one preferred testosterone product (typically a generic topical gel or injectable testosterone cypionate), and (4) a clinical reason Jatenzo is medically necessary over the preferred alternatives. The PA review timeline is typically 3, 10 business days through Arkansas DHS [9].

Private insurance. Most commercial plans in Arkansas classify Jatenzo as a Tier 3 or Tier 4 specialty drug. Copays range from $60, $200/month after deductibles on plans with standard specialty tiers. PA requirements parallel those described for Medicaid.

Blood Pressure Monitoring: The Critical Safety Step Arkansas Patients Often Miss

Jatenzo carries a boxed warning about blood pressure elevation. The FDA prescribing information states the drug "can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death" [1]. In the Swerdloff 2020 trial, 21% of participants experienced a blood pressure-related adverse event during the study [2].

Arkansas patients starting Jatenzo should document home blood pressure at baseline, at week 3, 4 (the first titration visit), and at each follow-up thereafter. If systolic BP exceeds 135 mmHg on two separate readings, the prescriber should evaluate whether antihypertensive therapy is needed before continuing Jatenzo or whether a different TRT modality is more appropriate.

The American Heart Association's 2017 hypertension guideline classifies stage 1 hypertension as systolic 130 to 139 mmHg [10]. Any Arkansas patient with pre-existing stage 2 hypertension (systolic 140+ mmHg) should have blood pressure controlled before Jatenzo initiation. The FDA label lists uncontrolled hypertension as a contraindication [1].

A home blood pressure cuff costs $25, $50 at any Arkansas Walmart or pharmacy. Patients should bring a log of at least four readings (two mornings, two evenings) to each follow-up telehealth visit.

Dose Titration Schedule After Starting Jatenzo in Arkansas

The FDA-approved titration protocol proceeds in three steps based on a serum testosterone drawn 3 to 5 hours after the morning dose [1]:

• If testosterone is <300 ng/dL: increase from 237 mg twice daily to 396 mg twice daily
• If testosterone is 300, 1 to 000 ng/dL: maintain 237 mg twice daily
• If testosterone is >1 to 000 ng/dL: decrease from 237 mg twice daily to 158 mg twice daily

After the first titration, repeat the same serum testosterone check (3 to 5 hours post-morning dose) at 3 to 4 weeks after any dose change. If testosterone remains outside range at maximum dose or cannot be controlled at minimum dose, Jatenzo may not be the appropriate formulation for that patient.

Swerdloff et al. (2020) reported that 75.2% of subjects achieved the target range at the 237 mg starting dose; 8.4% required uptitration to 396 mg; and 16.4% required downtitration to 158 mg [2]. Most Arkansas patients will stay at the starting dose.

Transferring an Existing Jatenzo Prescription to Arkansas

Patients relocating to Arkansas from another state face a straightforward process. Jatenzo is a Schedule III controlled substance, which means:

• Federal law (21 USC § 829) allows a pharmacist in Arkansas to accept a valid Schedule III prescription issued by a licensed out-of-state prescriber, subject to Arkansas Pharmacy Practice Act requirements [11].
• The prescription must be current (not expired), legible, and contain all required elements including DEA number.
• Arkansas pharmacies can dispense the remaining authorized refills on a Schedule III prescription from an out-of-state provider.
• For ongoing care, the patient should establish with an Arkansas-licensed prescriber (including via telehealth) before the prescription expires, because Schedule III prescriptions expire six months from the date of issue in most states and cannot be refilled after expiration.

The simplest transfer pathway for most patients is: fill the remaining refills at an Arkansas retail pharmacy, and simultaneously start the telehealth intake process with an Arkansas provider so coverage is continuous.

Hematocrit and PSA Monitoring During Ongoing Jatenzo Therapy

Ongoing monitoring matters as much as baseline labs. The Endocrine Society 2018 guideline recommends checking hematocrit at 3 to 6 months after starting testosterone therapy and annually thereafter [3]. The FDA label for Jatenzo specifies that if hematocrit exceeds 54%, therapy should be withheld until it falls to a safe level, then restarted at a lower dose [1].

PSA monitoring frequency follows American Urological Association (AUA) age-based prostate cancer screening guidelines. For men 55, 69, PSA should be checked at 3 to 6 months after starting Jatenzo and annually thereafter [12]. A PSA rise greater than 1.4 ng/mL from baseline over any 12-month period warrants urology referral before continuing testosterone therapy [3].

The CDC's National Center for Health Statistics data shows Arkansas has above-average rates of cardiovascular disease and obesity compared to the national median [13]. That population context means Arkansas prescribers should be especially attentive to the cardiovascular monitoring requirements that accompany Jatenzo use.

Cost-Reduction Strategies Available to Arkansas Patients

Jatenzo is not inexpensive without assistance. Four approaches reduce out-of-pocket costs for Arkansas patients:

Tolmar patient assistance. Tolmar's JatenzoCares savings card is available to commercially insured patients who do not use federal or state insurance (Medicare, Medicaid, TRICARE). It can reduce monthly cost to as low as $0 for eligible patients [7].

Prior authorization appeal. If a commercial insurer denies PA for Jatenzo, Arkansas law (Act 235 of 2019) requires insurers to provide a written denial with a specific clinical reason and a clear appeal pathway. Prescribers can submit a peer-to-peer review request, which overturns denials approximately 30 to 50% of the time based on general specialty pharmacy PA appeal data.

GoodRx and similar discount programs. These apply only when paying cash; they cannot be combined with insurance. GoodRx coupons for Jatenzo are accepted at most major Arkansas chain pharmacies.

Formulary exception request. For Arkansas Medicaid patients who cannot take generic testosterone cypionate due to injection phobia or a documented skin condition preventing topical use, a formulary exception citing medical necessity may move Jatenzo to a lower cost-sharing tier.